Tissue Repair Ltd Sees Robust Sales and Advancements

Tissue Repair Ltd (AU:TRP) has released an update.

Tissue Repair Ltd, listed on the ASX, reported a surge in TR Pro+® sales by 27% over the previous quarter, marking strong market acceptance with over 240 clinics placing orders. The company is advancing its TR987® treatment for chronic wounds, with significant progress in clinical trial preparations and the production of the Glucoprime® API. The company’s cash position remains robust at $15.9 million as of September 2024, despite net cash outflows driven by ongoing development and commercialization efforts.

For further insights into AU:TRP stock, check out TipRanks’ Stock Analysis page.